

## Sponsored Symposium

**Date** Friday, 26 November 2021/ 20:15~21:00 (JST)

**Venue** Online

# New Treatment Options in NMOSD

[PRESCRIBING INFORMATION in Japan]

●Indications of Inebilizumab

Prevention of relapses of neuromyelitis optica spectrum disorder (including neuromyelitis optica)

•Precautions Related to Indications of Inebilizumab

This drug should be used in patients with neuromyelitis optica spectrum disorder (including neuromyelitis optica)\*.

\*Refer to "Clinical Practice Guidelines for Multiple Sclerosis/Neuromyelitis Optica 2017" (Japanese Society of Neurology).

There are limited data demonstrating efficacy in patients who are anti-aquaporin-4 (AQP4) antibody-negative. This drug should be administered to patients who are anti-AQP4 antibody positive.

Chair

**Kazuo Fujihara, MD**

Professor, Department of Multiple Sclerosis Therapeutics,  
Fukushima Medical University School of Medicine, and Director, Multiple Sclerosis &  
Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan

Speaker1

## CD19-targeted B-cell depleting Therapy: Impact in the NMOSD World

**Hirofumi Ochi, MD, PhD**

Associate Professor in Neurology and Geriatric Medicine,  
Ehime University Graduate School of Medicine

Speaker2

## The long-term benefits of Inebilizumab

**Ho Jin Kim, MD, PhD**

Head of Department of Neurology and Division of Clinical Research  
Professor of Department of Cancer Biomedical Science, Graduate School of Cancer Science & Policy  
National Cancer Center, Goyang, Korea